ClinicalTrials.gg
RecruitingNCT07650188StABUpdated Jun 16, 2026

Stimulating the Aging Brain Using Brain and Sensory Stimulation

An interventional study of tACS or multisensory stimulation in Primary Progressive Aphasia, sponsored by Medical College of Wisconsin. Recruiting at 1 site in United States. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Medical College of Wisconsin · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Aphasia, Primary Progressive with a site in United States — 20 open to participants now, 24 under way, none of them phase 3. Aphasia, Primary Progressive · United States.

Planned enrollment
26th of 43
20 · median 30
Started
2026
with 2 others
No phase
31 of 51
10 open now
Primary completion
2031-05
later than 21 of 23 live
Registered
50th of 51
by date
Lead sponsor
2 of 51
Medical College of Wisconsin

Among the 51 studies in Aphasia, Primary Progressive with a site in United States, this one is the 26th largest by planned enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2026, is one of 31 with no phase, reaches primary completion later than 21 of the 23 other live ones, and was the 50th registered.

Aphasia, Primary Progressive

77 studies on the registry are indexed under Aphasia, Primary Progressive; 28 are open to participants now.

Browse Aphasia, Primary Progressive studies →

Open to participants now

20 of the 51 studies in Aphasia, Primary Progressive with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Aphasia, Primary Progressive studies recruiting now, 13 (54%) set no upper age limit and 1 (4%) stops at 75 or younger; 1 takes children under 18; 10 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Aphasia, Primary Progressive with a site in United States, or all of them as a file.
02

Study summary

The goal of this project is to investigate whether transcranial electrical stimulation and sensory stimulation affect language outcomes in individuals with primary progressive aphasia (PPA). The main questions it aims to answer are:

Does transcranial alternating current stimulation (tACS) affect verbal short-term memory (STM) in individuals with PPA? Does a single session of multisensory stimulation affect verbal STM in individuals with PPA? Researchers will compare active tACS to sham tACS (a fake stimulation condition) to see if active tACS improves verbal STM. Researchers will compare pre-multisensory stimulation to post-stimulation performance to see if multisensory stimulation improves verbal STM.

Participants will:

Undergo EEG, MRI (anatomical and functional) May complete a cognitive exam Undergo tACS over 3 separate sessions Undergo multisensory stimulation Complete language tasks before, during and/or after stimulation

Read the detailed description

The primary objective of the current project is to examine the effects of tACS and multisensory stimulation on verbal STM outcomes in individuals with PPA. The selection of parameters will be guided on the basis of oscillatory brain activity using language task-based or task-free EEG paradigms. Neuroimaging (MRI and functional MRI) will guide spatial targets of tACS. A secondary objective is to explore sources of individual variability in response to stimulation and whether these factors could offer insight into disease progression. This proof-of-concept, pilot project will generate essential preliminary data to help refine hypotheses for future clinical trials aimed at assessing the efficacy of these intervention strategies in predicting and treating (as in delaying) disease progression.

03

Conditions studied

  • Primary Progressive Aphasia

Keywords

  • Transcranial alternating current stimulation
  • Multisensory stimulation
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical exam supports diagnosis of PPA and/or MCI with no report of difficulty functioning in basic or instrumental activities of daily living.
  • Completed clinical cognitive exam within 6 months of study baseline visit OR neuropsychological research battery within 6 months of study baseline visit.

Exclusion criteria

Exclusion Criteria:

  • Evidence of dementia at baseline
  • Known history of neoplasm, symptomatic stroke, moderate to severe traumatic brain injury, or other significant neurologic event
  • Age \<45 years.
  • Evidence of severe psychiatric illness (e.g., bipolar disorder, schizophrenia).
  • Presence of cardiac stimulators or pacemakers
  • Any other implants near the scalp or in the eye
  • to MRI or stimulation
  • Pregnancy
  • History of ongoing or unmanaged seizures
  • History of dyslexia or other developmental learning disabilities
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    tACS or multisensory stimulation

    All participants in a within-subject design will receive high-Definition-tACS, delivered via a battery operated alternating current stimulator (Soterix) using two center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion over approximately 30 seconds. Participants will undergo tACS with frequencies ranging from 4-40Hz for 20-minutes with 2 milliampere (mA) peak-to-peak intensity. For sham stimulation, tACS is turned off after the first 30 seconds. All participants will receive light and/or sound flicker stimulation using an off-the-shelf app for 20 minutes.

    Device: tACS or multisensory stimulation

Interventions

  • DevicetACS or multisensory stimulation

    Active or sham tACS Light and/or sound flickers

06

What researchers measure

Primary outcomes

  1. Changes in STM capacity assessed using a verbal STM task

    Improvement in STM capacity with in-phase tACS and worsening of STM capacity with anti-phase tACS compared to sham tACS

    Time frame: Changes monitored over pre, during and immediately after 20 minutes of tACS

  2. Changes in STM capacity with multisensory stimulation using a verbal STM task

    Improvement in STM capacity post-stimulation compared to pre-stimulation

    Time frame: Changes monitored pre and immediately after 20 minutes of stimulation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Hu J, Zheng L, Guan Z, Zhong K, Huang F, Huang Q, Yang J, Li W, Li S. Sensory gamma entrainment: Impact on amyloid protein and therapeutic mechanism. Brain Res Bull. 2023 Oct 1;202:110750. doi: 10.1016/j.brainresbull.2023.110750. Epub 2023 Aug 23. PubMed 37625524 ↗
  • Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J, Kritskiy O, Abdurrob F, Adaikkan C, Canter RG, Rueda R, Brown EN, Boyden ES, Tsai LH. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. 2016 Dec 7;540(7632):230-235. doi: 10.1038/nature20587. PubMed 27929004 ↗
  • Martorell AJ, Paulson AL, Suk HJ, Abdurrob F, Drummond GT, Guan W, Young JZ, Kim DN, Kritskiy O, Barker SJ, Mangena V, Prince SM, Brown EN, Chung K, Boyden ES, Singer AC, Tsai LH. Multi-sensory Gamma Stimulation Ameliorates Alzheimer's-Associated Pathology and Improves Cognition. Cell. 2019 Apr 4;177(2):256-271.e22. doi: 10.1016/j.cell.2019.02.014. Epub 2019 Mar 14. PubMed 30879788 ↗
  • McNett SD, Vyshedskiy A, Savchenko A, Durakovic D, Heredia G, Cahn R, Kogan M. A Feasibility Study of AlzLife 40 Hz Sensory Therapy in Patients with MCI and Early AD. Healthcare (Basel). 2023 Jul 17;11(14):2040. doi: 10.3390/healthcare11142040. PubMed 37510481 ↗
  • Tang Y, Xing Y, Sun L, Wang Z, Wang C, Yang K, Zhu W, Shi X, Xie B, Yin Y, Mi Y, Wei T, Tong R, Qiao Y, Yan S, Wei P, Yang Y, Shan Y, Zhang X, Jia J, Teipel SJ, Howard R, Lu J, Li C, Zhao G. TRanscranial AlterNating current stimulation FOR patients with mild Alzheimer's Disease (TRANSFORM-AD): a randomized controlled clinical trial. Alzheimers Res Ther. 2024 Sep 12;16(1):203. doi: 10.1186/s13195-024-01570-0. PubMed 39267112 ↗
  • Altomare D, Benussi A, Cantoni V, Premi E, Rivolta J, Cupidi C, Martorana A, Santarnecchi E, Padovani A, Koch G, Borroni B. Home-based transcranial alternating current stimulation (tACS) in Alzheimer's disease: rationale and study design. Alzheimers Res Ther. 2023 Sep 15;15(1):155. doi: 10.1186/s13195-023-01297-4. PubMed 37715232 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for May 2031, 59 months after the start.

Of 38 non-industry interventional studies with no phase under Aphasia, Primary Progressive, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 59. This study's planned 59 months is above that.

Counting every sponsor, half of 38 studies reached it within 40 months; a quarter within 26 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 16, 2026
StartActual
Jun 1, 2026
Primary completionEst.
May 30, 2031
CompletionEst.
May 30, 2035
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07650188
Responsible party
Priyanka Shah-Basak, PhD (Assistant Professor of Neurology, Medical College of Wisconsin) — Principal investigator
First posted
Jun 16, 2026
Start date
Jun 1, 2026
Primary completion
May 30, 2031 (estimated)
Completion
May 30, 2035 (estimated)
Last update
Jun 16, 2026

Study contacts

Sidney Schoenrock, MA
Contact
sschoenrock@mcw.edu
414-955-7579
Priyanka Shah-Basak, PhD
principal investigator · Medical College of Wisconsin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion